FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Walton

Research Profile

Chemicals & Drugs

Phenomena

Blotting, Western

Anatomy

Concepts & Ideas

Co-author Network

Publications

TOP 3
Nathalie Gaspar; Swee Y Sharp; Simon Pacey; Chris Jones; Michael Walton; Gilles Vassal; Suzanne A Eccles; Andrew Pearson; Paul Workman
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Udai Banerji; Nivedita Sain; Swee Y Sharp; Melanie Valenti; Yasmin Asad; Ruth Ruddle; Florence I Raynaud; Michael Walton; Suzanne A Eccles; Ian Judson; Ann L Jackman; Paul Workman
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
Alison Maloney; Paul A Clarke; Soren Naaby-Hansen; Rob Stein; Jens Koopm,ann; Akunna Akpan; Alice Yang; Marketa Zvelebil; Rainer Cramer; Lindsay Stimson; Wynne Aherne; Udai Banerji; Ian Judson; Swee Sharp; Marissa Powers; Emmanuel deBilly; Joanne Salmons; Michael Walton; Al L Burlingame; Michael D Waterfield; Paul Workman
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Walton (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Nathalie Gaspar; Swee Y Sharp; Simon Pacey; Chris Jones; Michael Walton; Gilles Vassal; Suzanne A Eccles; Andrew Pearson; Paul Workman
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Cancer research 2009;69(5):1966-75.
2008: Udai Banerji; Nivedita Sain; Swee Y Sharp; Melanie Valenti; Yasmin Asad; Ruth Ruddle; Florence I Raynaud; Michael Walton; Suzanne A Eccles; Ian Judson; Ann L Jackman; Paul Workman
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
Cancer chemotherapy and pharmacology 2008;62(5):769-78.
2007: Alison Maloney; Paul A Clarke; Soren Naaby-Hansen; Rob Stein; Jens Koopm,ann; Akunna Akpan; Alice Yang; Marketa Zvelebil; Rainer Cramer; Lindsay Stimson; Wynne Aherne; Udai Banerji; Ian Judson; Swee Sharp; Marissa Powers; Emmanuel deBilly; Joanne Salmons; Michael Walton; Al L Burlingame; Michael D Waterfield; Paul Workman
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Cancer research 2007;67(7):3239-53.
2005: Udai Banerji; Michael Walton; Florence I Raynaud; Rachel Grimshaw; Lloyd R Kelland; Melanie Valenti; Ian Judson; Paul Workman
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):7023-32.
2005: Udai Banerji; Anne O'Donnell; Michelle Scurr; Simon Pacey; Sarah Stapleton; Yasmin Asad; Laura Simmons; Alison Maloney; Florence I Raynaud; Maeli Campbell; Michael Walton; Sunil Lakhani; Stan Kaye; Paul Workman; Ian Judson
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4152-61.
2000: Paul A Clarke; I Hostein; Udai Banerji; F D Stefano; Alison Maloney; Michael Walton; Ian Judson; Paul Workman
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
Oncogene 2000;19(36):4125-33.